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Introduction 
Zidovudine and tenofovir form the back bone of antiretroviral therapy in Kenya, with sub-Sahara Africa 
having the highest prevalence of HIV worldwide. However, they have side effects which may 
adversely affect  health related quality of life (HRQoL) and adherence. More women than men have 
HIV in sub-Sahara Africa; consequently, crucial to conduct studies in Africa. Objective: Compare the 
Health Related Quality of Life of adult patients on tenofovir versus zidovudine based regimens in a 
leading referral hospital in Kenya to guide future management decisions. Methods: Comparative 
cross sectional study conducted on adult out-patients on either tenofovir or zidovudine at Kenyatta 
National Hospital between 2015 and 2016. The Medical Outcome Study HIV Health Survey (MOS) 
was administered. Linear regression analysis was performed to identify determinants of HRQoL. 
Results: Of the total 501 patinets included, participants on zidovudine (39.9%, n=200) had a higher 
median Physical (PHS) and Mental Health Scores (MHS) (61.9, IQR: 59.5, 62.8) compared to those 
on tenofovir (60.1, IQR: 55.1, 62.3).  Presence of any symptom of disease and stated inability to cope 
were negatively associated with PHS whilst having regular source of income improved PHS. Being on 
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0.152, 0.674) and patient stated inability to cope with HIV ȕ-1.029, 95 % CI; -1.441, -0.617) affected 
the MHS. Patients on tenofovir and second line regimens also had more signs and symptoms of 
illness. Conclusion: Participants on zidovudine based regimens had a better performance across all 
aspects of HRQoL, and should be actively considered in the future where pertinent.    
 
